RBC Capital raised the firm’s price target on Pharming (PHAR) to EUR 2.45 from EUR 2 and keeps an Outperform rating on the shares.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHAR:
- Pharming price target raised to $41 from $40 at Oppenheimer
- Pharming Group’s Strong Financial Performance and Strategic Developments Justify Buy Rating
- Pharming Group Reports Strong Q2 2025 Revenue Growth
- Pharming Group Reports Strong Q2 2025 Financial Results and Business Update
- Pharming Group’s Growth Potential Boosted by Advances in APDS Diagnosis and Treatment